Aventis to launch Ketec, an antibiotic in July.

Published: 2004-07-02 06:58:00

Updated: 2004-07-02 06:58:00

Aventis will launch Ketec (Telythromycin), an oral antibiotic, in the market from July 1 for the first time over the world, which was specifically developed for the treatment of regional acquired respiratory tract infections. Its effect can be expected by a daily one a day dose for 5 day treatmen...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK